Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, FSH binds to receptors on granulosa cells, promoting follicle growth and estrogen synthesis, while LH activates receptors on theca cells and mature follicles, supporting androgen production and final oocyte maturation, together leading to ovulation.

The specific dose of Menopur is individualized by the treating physician based on the patient’s ovarian reserve, treatment protocol and response to monitoring. The prescriber determines the number of international units (IU) per injection and the total duration of therapy, adjusting as needed throughout the stimulation cycle.

Menopur is intended for use before conception and is not administered during an established pregnancy. Its safety in pregnancy has not been established, and it is generally avoided once pregnancy is confirmed. Limited data are available for breastfeeding; therefore, use while nursing is not recommended without specialist advice.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and the necessary import documentation.

The primary alternative to Menopur is recombinant FSH (rFSH) products such as follitropin alfa. Menotropin provides both FSH and LH activity in a single preparation, which can simplify dosing compared with separate recombinant FSH and LH agents. Recombinant products offer higher purity and batch‑to‑batch consistency, while Menotropin is derived from urinary sources and may be more cost‑effective in some markets.

Menopur must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Before use, allow the product to reach room temperature for a few minutes; avoid using any vial that appears cloudy or contains particles.

Menopur is supplied as a sterile injection solution for subcutaneous administration. The prescribed dose is drawn into a sterile syringe and injected into the subcutaneous tissue of the abdomen or thigh, typically once daily or as directed by the fertility specialist. Injection technique and site rotation should follow standard clinical guidelines.

The most serious risks associated with Menopur include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, shortness of breath, and fluid accumulation; thromboembolic events such as deep‑vein thrombosis or pulmonary embolism; and rare allergic reactions that may progress to anaphylaxis. Prompt medical attention is required if any of these symptoms develop.

Menopur is contraindicated in women with active or uncontrolled ovarian or breast cancer, severe uncontrolled thyroid disease, uncontrolled hypertension, or significant cardiovascular disease. It should also be avoided in patients with known hypersensitivity to menotropin or any component of the formulation, and in women who are already pregnant.